Selective CDK4 Inhibitors With Reduced CDK6 Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CDK4/6 inhibitors face limitations such as resistance, toxicity, and lack of targeted therapy for CDK2 dysregulation in various cancers, necessitating a compound with improved selectivity and efficacy, particularly for CDK4 over CDK6, and minimal CDK1 inhibition.
Innovation Solution
Development of compounds with specific structures (Formula I) that selectively inhibit CDK4 over CDK6 and CDK2, exhibiting favorable pharmacokinetics and safety profiles, including excellent solubility and reduced hematological toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dual CDK4/6 inhibitors are used, then cell cycle progression is inhibited, but neutropenia toxicity occurs due to CDK6 inhibition
Solution Approach 1:
The patent applies local quality by creating a compound with differentiated inhibition strengths against CDK4 and CDK6. The compound selectively inhibits CDK4 with high potency while exhibiting reduced inhibition against CDK6, allowing targeted suppression of tumor cell proliferation with minimized impact on hematopoietic cells that depend on CDK6
Solution Approach 2:
The patent utilizes parameter changes by modifying the chemical structure (specifically the R1 substituent variations) to tune the inhibition profile. By adjusting molecular parameters such as substituent groups on the pyrimidine core, the compound achieves optimal binding affinity for CDK4 while reducing off-target effects on CDK6
2Reliability
If CDK1 inhibition is increased, then cell cycle regulation is enhanced, but essential cell cycle functions are disrupted
Solution Approach 1:
The patent applies the taking out principle by selectively extracting and inhibiting only the pathological CDK4 activity while leaving essential CDK1 functions intact. The compound is designed to bind specifically to CDK4's ATP-binding site without significantly interacting with CDK1, thereby removing the harmful proliferative signal while preserving necessary cell cycle regulation
3Reliability
If compound selectivity for CDK4 over CDK6 is improved, then therapeutic index is enhanced, but compound structure complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically varying substituents on the pyrimidine core (R1 positions) to optimize the balance between selectivity and structural simplicity. Different alkyl, haloalkyl, and heteroaryl groups are explored to achieve the desired inhibition profile with manageable molecular complexity
Solution Approach 2:
The patent utilizes composite material principles by combining a core pyrimidine structure with specific substituent groups that collectively provide both CDK4 selectivity and appropriate pharmacokinetic properties. The composite molecular architecture integrates multiple functional elements that work synergistically to achieve the desired therapeutic profile
4Reliability
If CDK2 inhibitory activity is increased, then cancer cell efficacy is improved, but off-target effects may increase
Solution Approach 1:
The patent applies local quality by creating a compound with differentiated inhibition strengths against CDK4, CDK6, and CDK2. The compound exhibits potent CDK4 inhibition with selective reduction of CDK6 and CDK2 activity, allowing targeted suppression of tumor cell proliferation pathways while minimizing disruption to other cellular processes dependent on these kinases
Data Source
AI summary
The invention relates to compounds which inhibit Cyclin-Dependent Kinases such as CDK2 (Cyclin-Dependent Kinase 2 or Cell Division protein Kinase 2) and CDK4 (Cyclin-Dependent Kinase 4 or Cell Division protein Kinase 4), and to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by CDK2 and/or CDK4.